Using the epigenetic field defect to detect prostate cancer in biopsy negative patients

Journal of Urology

Volumn 189, Issue 6, 2013, Pages 2335-2341

  Truong, Matthew ^a   Yang, Bing ^a   Livermore, Andrew ^a   Wagner, Jennifer ^a   Weeratunga, Puspha ^a   Huang, Wei ^a   Dhir, Rajiv ^b   Nelson, Joel ^b   Lin, Daniel W ^c   Jarrard, David F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

biopsy; diagnosis; epigenomics; prostate; prostatic neoplasms

Indexed keywords

CAVEOLIN 1; EVENSKIPPED HOMEOBOX 1 PROTEIN; FIBROBLAST GROWTH FACTOR 1; PROSTATE SPECIFIC ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETIC FIELD DEFECT; EPIGENETICS; GENETIC ASSOCIATION; GENETIC MARKER; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PYROSEQUENCING; TRANSRECTAL ULTRASOUND GUIDED BIOPSY; UNIVERSITY HOSPITAL; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; DNA METHYLATION; EPIGENOMICS; FIBROBLAST GROWTH FACTOR 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; REFERENCE VALUES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TISSUE CULTURE TECHNIQUES;

EID: 84877612957     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.11.074     Document Type: Article

References (29)

1. J. Mehrotra, S. Varde, H. Wang Quantitative, spatial resolution of the epigenetic field effect in prostate cancer Prostate 68 2008 152
2. G.D. Dakubo, J.P. Jakupciak, M.A. Birch-Machin Clinical implications and utility of field cancerization Cancer Cell Int 7 2007 2
3. I.M. Thompson, D.K. Pauler, P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter N Engl J Med 350 2004 2239
4. D.J. Rosario, J.A. Lane, C. Metcalfe Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study BMJ 344 2012 d7894
5. P.H. Gann, A. Fought, R. Deaton Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach J Clin Oncol 28 2010 1714
6. G.L. Lee, A. Dobi, S. Srivastava Prostate cancer: diagnostic performance of the PCA3 urine test Nat Rev Urol 8 2011 123
7. W.G. Nelson, A.M. De Marzo, S. Yegnasubramanian Epigenetic alterations in human prostate cancers Endocrinology 150 2009 3991
8. Yang BB, Kueck J, Weeratunga P, et al. Methylation profiling defines a widespread field defect in histologically normal prostate tissues associated with prostate cancer. Unpublished data.
9. A. Aitchison, A. Warren, D. Neal RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues Prostate 67 2007 638
10. I. Steiner, K. Jung, P. Schatz Gene promoter methylation and its potential relevance in early prostate cancer diagnosis Pathobiology 77 2010 260
11. J.A. Hanson, J.W. Gillespie, A. Grover Gene promoter methylation in prostate tumor-associated stromal cells J Natl Cancer Inst 98 2006 255
12. S. Bhusari, B. Yang, J. Kueck Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer Prostate 71 2011 1621
13. L. Nonn, V. Ananthanarayanan, P.H. Gann Evidence for field cancerization of the prostate Prostate 69 2009 1470
14. M.C. Risk, B.S. Knudsen, I. Coleman Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect Clin Cancer Res 16 2010 5414
15. C.M. Heaphy, T.M. Fleet, E.G. Treat Organ-wide telomeric status in diseased and disease-free prostatic tissues Prostate 70 2010 1471
16. T.D. Jones, M. Wang, J.N. Eble Molecular evidence supporting field effect in urothelial carcinogenesis Clin Cancer Res 11 2005 6512
17. E. Giovannucci, S. Ogino DNA methylation, field effects, and colorectal cancer J Natl Cancer Inst 97 2005 1317
18. S. Yegnasubramanian, J. Kowalski, M.L. Gonzalgo Hypermethylation of CpG islands in primary and metastatic human prostate cancer Cancer Res 64 2004 1975
19. M. Truong, B. Yang, J. Wagner Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence Br J Cancer 107 2012 100
20. J. Cui, L.R. Rohr, G. Swanson Hypermethylation of the caveolin-1 gene promoter in prostate cancer Prostate 46 2001 249
21. J.R. Graff, J.G. Herman, S. Myöhänen Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation J Biol Chem 272 1997 22322
22. N. Turner, R. Grose Fibroblast growth factor signalling: from development to cancer Nat Rev Cancer 10 2010 116
23. B.J. Trock, M.J. Brotzman, L.A. Mangold Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies BJU Int 110 2012 56
24. D.A. Troyer, M.S. Lucia, A.P. de Bruïne Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies Cancer Epidemiol Biomarkers Prev 18 2009 2717
25. G.D. Stewart, L. Van Neste, P. Delvenne Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study J Urol 189 2013 1110
26. Y.P. Yu, D. Landsittel, L. Jing Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy J Clin Oncol 22 2004 2790
27. C.M. Moore, N.L. Robertson, N. Arsanious Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review Eur Urol 63 2013 125
28. J.M. Taylor, D.P. Ankerst, R.R. Andridge Validation of biomarker-based risk prediction models Clin Cancer Res 14 2008 5977
29. B. Djavan, V. Ravery, A. Zlotta Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 2001 1679